Soleno Therapeutics Faces Securities Class Action Over Drug Launch Issues

Legal Troubles for Soleno Therapeutics: A Deep Dive into the Class Action Lawsuit

Soleno Therapeutics, Inc., a biopharmaceutical company specializing in treatments for rare genetic disorders, finds itself entangled in a securities class action lawsuit that underscores the pressing issues surrounding its recently launched hyperphagia treatment, DCCR, also known as VYKAT™ XR. The lawsuit, initiated by national shareholder rights law firm Hagens Berman, aims to represent investors who purchased Soleno's common stock between March 26, 2025, and November 4, 2025.

The crux of the case revolves around allegations that Soleno misled investors regarding the safety, efficacy, and commercial viability of DCCR, a medication intended to address hyperphagia, a severe and life-altering symptom of Prader-Willi Syndrome (PWS). Reports indicate that on November 5, 2025, following a disappointing update on DCCR's market performance, Soleno's stock witnessed a dramatic 26% drop in a single day, marking a significant loss for many investors.

Understanding the Drug and Its Controversy

DCCR was introduced as a once-daily oral treatment for hyperphagia, a condition characterized by an insatiable appetite and severe complications affecting individuals with PWS. Soleno claimed the launch was going exceptionally well, providing assurances that their projections exceeded expectations. However, the allegations suggest a stark contrast between the company's communications and the reality on the ground.

Since the release of an August 15, 2025, report by activist short seller Scorpion Capital, questions surrounding the transparency of Soleno's disclosures have gained traction. The Scorpion report highlighted alarming trends, including an increasing number of hospitalizations among children using DCCR, raising doubts about the medication's safety profile. Notably, the report suggested the launch metrics presented by Soleno might be misleading, pointing to a reliance on a single controversial physician associated with the treatment’s trials as a potential conflict of interest.

The Stock's Roller Coaster Journey

From a financial perspective, the launch of DCCR has been roller-coaster for investors. With the stock dropping nearly 40% since the revelations at the end of August 2025, faith in Soleno's management and their strategic decisions is seriously under scrutiny. This profound decline reflects broader concerns regarding the drug's commercial prospects, safety data integrity, and the company's obligation to a transparent investor relationship.

As the class action progresses, Hagens Berman continues to investigate potential violations of federal securities laws by Soleno. They are committed to uncovering whether the company intentionally obscured information regarding the safety and efficacy of DCCR, potentially misleading investors about its commercial viability.

What Investors Should Know

Investors who believe they have incurred significant losses due to Soleno's alleged misrepresentations are encouraged to take action. The class period for the lawsuit is from March 26, 2025, to November 4, 2025, with a lead plaintiff deadline set for May 5, 2026. Those affected can connect with law firm Hagens Berman to assess their options for recovering losses linked to their investments in Soleno shares.

Moving Forward

As we look toward the outcome of this class action, it sheds light on the importance of transparency and ethical practices in the pharmaceutical industry. Investors are reminded of the inherent risks associated with investing in biopharmaceutical companies, particularly those involved in developing treatments for complex and under-researched conditions like PWS. As the case unfolds, the spotlight will squarely be on Soleno Therapeutics to demonstrate its commitment to accountability and integrity, not only to its investors but also to the vulnerable communities it aims to serve.

In conclusion, the challenges faced by Soleno Therapeutics bring forth crucial conversations about corporate responsibility. For now, it remains to be seen how the legal landscape will evolve, and what this will mean for both investors and the patients relying on Soleno's treatments.